Imugene (ASX:IMU) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application number that protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR-T cell therapies. …
Latest Video
New Stories
-
The 'Dispatched' Week in Review - 12 September
September 12, 2025 - - Podcast -
Surely this is what the collapse of moral authority must look like
September 11, 2025 - - Latest News -
Artificial Intelligence can only accelerate Health Technology Assessments
September 11, 2025 - - Latest News -
Australian biotechs shine at Asia Pacific Cell and Gene Therapy Awards
September 11, 2025 - - Australian Biotech -
Trump administration announces new disclosure rules for medicine advertising
September 10, 2025 - - Latest News -
Chemist Warehouse partners with DoorDash to deliver health and beauty on demand
September 10, 2025 - - Latest News -
Cancer leaders unite to tackle equity and innovation at 2025 PCPA Summit
September 10, 2025 - - Latest News